Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for iBio, Inc. (IBIO:NASDAQ), powered by AI.
iBio, Inc. is currently trading at $1.55. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for iBio, Inc. on Alpha Lenz.
iBio, Inc.'s P/E ratio is -0.9.
“iBio, Inc. trades at a P/E of -0.9 (undervalued) with modest ROE of -101.5%.”
Ask for details →iBio, Inc. is a biotechnology company that focuses on the development and commercialization of plant-based biopharmaceuticals. Leveraging proprietary technologies and a unique platform called FastPharming, iBio accelerates the production of recombinant proteins for use in vaccines, therapeutics, and diagnostics. This platform capitalizes on the rapid growth and scalability of plants to offer a sustainable alternative to traditional drug manufacturing. iBio's operations are particularly relevant in healthcare sectors addressing urgent needs, such as infectious disease prevention and cancer treatment. Situated at the intersection of biotech innovation and agribusiness, the company's contributions are vital in enhancing production efficiencies and reducing costs associated with pharmaceutical development. iBio, Inc., by integrating plant-based solutions, is progressively impacting markets where rapid response and cost-effective production are critical factors.
“iBio, Inc. trades at a P/E of -0.9 (undervalued) with modest ROE of -101.5%.”
Ask for details →iBio, Inc. (ticker: IBIO) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 20 employees. Market cap is $16M.
The current price is $1.55 with a P/E ratio of -0.89x and P/B of 1.09x.
ROE is -101.52% and operating margin is -4650.50%. Annual revenue is $400,000.